Exploration of imidazole and imidazopyridine dimers as anticancer agents: Design, synthesis, and structure–activity relationship study
作者:Sangeetha Meenakshisundaram、Manoj Manickam、Thanigaimalai Pillaiyar
DOI:10.1002/ardp.201900011
日期:2019.12
Dimerization of proteins/receptors plays a critical role in various cellular processes, including cell proliferation and differentiation. Therefore, targeting such dimeric proteins/receptors by dimeric small molecules could be a potential therapeutic approach to treating various diseases, including inflammation‐associated diseases like cancer. A novel series of bis‐imidazoles (13–18) and bis‐imidazo[1,2‐a]pyridines
蛋白质/受体的二聚化在各种细胞过程中起着关键作用,包括细胞增殖和分化。因此,通过二聚体小分子靶向此类二聚体蛋白/受体可能是治疗各种疾病(包括癌症等炎症相关疾病)的潜在治疗方法。一系列新型双咪唑 (13-18) 和双咪唑并 [1,2-a] 吡啶 (19-28) 因具有抗癌活性而由席夫碱二聚体 (1-12) 设计和合成。筛选了所有合成的化合物对三种癌细胞系的抗癌活性,包括宫颈癌 (HeLa)、乳腺癌 (MDA-MB-231) 和肾癌 (ACHN)。从构效关系研究中,咪唑并[1,2-a]吡啶(19-28)显示出显着的细胞毒活性,化合物 19 和 24 显示出对所有三种细胞系的最佳抑制活性。特别是,19 和 24 对乳腺癌细胞系都非常有效(19,GI50 = 0.43 µM;24,GI50 = 0.3 µM),超过了对照阿霉素的活性(GI50 = 0.51 µM)。化合物 19 和 24 的体内抗